Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more
Il Dong Pharmaceutical Co Ltd (249420) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.050x
Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) has a cash flow conversion efficiency ratio of 0.050x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩11.28 Billion) by net assets (₩226.84 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Il Dong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Il Dong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Il Dong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Il Dong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Comens New Materials
SHE:300200
|
0.010x |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
0.123x |
|
Global Industrial Co
NYSE:GIC
|
0.072x |
|
Columbus McKinnon Corporation
NASDAQ:CMCO
|
0.022x |
|
Kelly Services B Inc
NASDAQ:KELYB
|
0.029x |
|
Carter Bank and Trust
NASDAQ:CARE
|
0.028x |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
0.039x |
|
Strike Energy Limited
OTCGREY:STKKF
|
N/A |
Annual Cash Flow Conversion Efficiency for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Il Dong Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩159.06 Billion | ₩28.29 Billion | 0.178x | +184.66% |
| 2023-12-31 | ₩174.27 Billion | ₩-36.62 Billion | -0.210x | +22.21% |
| 2022-12-31 | ₩198.22 Billion | ₩-53.54 Billion | -0.270x | -281.61% |
| 2021-12-31 | ₩160.58 Billion | ₩-11.37 Billion | -0.071x | -193.03% |
| 2020-12-31 | ₩254.55 Billion | ₩19.37 Billion | 0.076x | -53.49% |
| 2019-12-31 | ₩252.89 Billion | ₩41.37 Billion | 0.164x | -32.06% |
| 2018-12-31 | ₩276.82 Billion | ₩66.65 Billion | 0.241x | -6.91% |
| 2017-12-31 | ₩285.07 Billion | ₩73.72 Billion | 0.259x | +50.98% |
| 2016-12-31 | ₩268.41 Billion | ₩45.98 Billion | 0.171x | -- |